Lytgobi savings card: $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Lytgobi

We didn’t find one.

Ask your pharmacy for Lytgobi’s cash price, and one or two other pharmacies too.
Lytgobi’s savings card works only with insurance from a job or one you bought.

Compare every option

Brand nameLytgobi

Authorized genericfutibatinib

Regular genericfutibatinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Lytgobi?

The original

–

Brand nameThe maker’s card

Taiho Oncology Patient Support (LYTGOBI Co-pay Program)

Savings card from Taiho Pharmaceutical (Taiho Oncology)

No insuranceNeeds insuranceNo cash price listed.

Insurance $0 a prescription

Or call 1-844-824-4648.

In the maker’s words

“$0 Co-pay program enrollment for eligible commercially insured patients…”

From the maker’s offer on lytgobi.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Lytgobi itself, from the same company, sold without the brand name, and usually for less. For now Lytgobi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Bile duct cancer in the liver with FGFR2 gene changes

What the FDA label says

LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Lytgobi (TAIHO PHARMACEUTICAL CO., LTD.), October 27, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/lytgobi/